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Introduction
The arthritic diseases are progressive and debilitating and 
impair the quality of life of patients. It is now common practice 
to use disease modifying agents early after a diagnosis is 
made to prevent irreversible joint damage. In recent years the 
biological DMARDS have been proven to be efficacious against 
the progression of rheumatoid arthritis (RA) when there is 
no response or a poor response to traditional DMARDs.1,2 An 
overview of the biological disease modifying agents available for 
use in South Africa is provided here. 
The biological DMARDS are effective when used as single 
agents but they are seldom used alone, since combinations 
with methotrexate have been shown to have clinical benefit.2 
Methotrexate use prevents the formation of antibodies to the 
biological agents, which extends their therapeutic lifespan. 
The prohibitive cost of the biological agents and their cost-
effectiveness remains an ongoing debate. In this context a 
recent Cochrane review indicates that methotrexate based small 
molecule triple therapy may be as efficacious as combinations of 
biological DMARDs with methotrexate.3
What are biological agents?
Biological DMARDs are protein molecules and include 
monoclonal antibodies and antibody based fusion proteins. 
Monoclonal antibodies bind to a specific molecular target, 
causing inactivation of the target and compete with the natural 
ligand for binding to the target, thereby preventing the function 
of the target molecule. Once a monoclonal antibody has 
associated with its target it triggers the antibody dependent 
cellular cytotoxic immune response and/or the complement 
system causing the removal/destruction of the target by the 
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immune system as shown in Figure 1. In the treatment of 
the arthritis group of diseases there are two main groups of 
biological agents available, the tumour necrosis factor-α (TNF-α) 
inhibitors and the non-TNF-α inhibitors of the immune system.
TNF-α as a drug target
TNF-α, a pro-inflammatory cytokine, was identified by Brennan 
et al in 1989 as an important target molecule in the inflamed 
synovium of rheumatoid arthritis patients.4 Since then clinical 
trials have proven that a decrease in circulating TNF-α levels 
decrease disease severity and preserve joint architecture in RA. 
Clinical trials proved TNF-α inhibitors to have equal efficacy to 
methotrexate when used alone and superior efficacy when used 
in combination with methotrexate. In addition, the combined use 
of TNF-α inhibitors and methotrexate prevents the formation of 
antibodies to the TNF-α inhibitors. The available TNF-α inhibitors 
bind to both soluble and membrane bound TNF-α.2,4
Adverse effects associated with TNF-α inhibitors are associated 
with the role of TNF-α in the immune system.  Of particular 
concern is the increased risk of infections, especially with 
organisms causing the formation of granulomas, like tuberculosis 
(TB) and histoplasmosis. In South Africa, the high TB burden 
makes it imperative to screen patients for latent and active 
infections prior to initiation of TNF-α therapy. It is advisable to 
immunize prospective patients against influenza, varicella zoster 
and pneumococcal disease.1 In addition, there is an increased 
risk for fungal viral and other bacterial infections. As with any 
immunosuppressive regimen, there is always a potential for 
the development of a malignancy, and patients require careful 
monitoring.5,6 
The use of TNF-α inhibitors has been associated with a spectrum 
of cutaneous reactions. Skin lesions range from injection site 
reactions to infections that are directly related to immune 
suppression, like bacterial cellulitis and Herpes zoster. Skin 
neoplasms and a host of immune mediated cutaneous diseases 
ranging from psoriasis to vasculitis and pemphigus are associated 
with TNF-α inhibition.7
TNF-α is secreted by monocytes, macrophages, T cells, B cells and 
fibroblasts and is important to the normal immune response. It is 
essential for both the formation and maintenance of granulomas 
in mycobacterial infections, explaining why latent infections 
are reactivated in patients treated with TNF-α inhibitors. TNF-α 
functions as a growth factor, induces the formation of pro-
inflammatory cytokines and endothelial adhesion molecules 
needed for leucocyte accumulation in tissues. TNF-α is essential 
for the defence against intracellular pathogens and functions as 
a co-mitogen for T and B cells.8
On a molecular level, TNF-α causes the trimerization of TNF-α 
receptors which activates signal transduction cascades that 
trigger apoptosis and orchestrate the translocation of the 
transcription factors AP-1 and NF-κB to the cell nucleus, as 
shown in Figure 2. AP-1 and NF-κB stimulate the transcription 
of numerous cytokine genes involved in the immune response.8 
TNF-α inhibitors
Etanercept
Etanercept is a recombinant fusion protein consisting of the 
TNF-α p75 receptor dimerized on the Fc portion of human IgG1. 
The TNF-α p75 region binds to soluble and membrane bound 
TNF-α. The presence of mouse amino-acid sequences induces 
an antibody response that decreases it function, therefore co-
administration of methotrexate is desirable.2,9
Etanercept use is associated with an increased risk for bacterial 
infections and septic arthritis. Compared to the other TNF-α 
inhibitors, reactivation of tuberculosis is less frequent with 
etanercept. The formation of anti-nuclear antibodies has been 
Figure 1. A summary of the consequences of monoclonal antibody 
binding to its specific receptor molecules. R: antibody specific receptor, 
McAB: monoclonal antibody, Fc: receptor binding to constant region of 
a monoclonal antibody, ADCC: antibody dependent cellular cytotoxicity
Figure 2. The multiple roles of TNF-α in the immune response. 
TNF-α forms a trimeric molecule which initiates the trimerization of 
its receptor molecules. This stimulates signal transduction cascades 
which result in the translocation of cytoplasmic transcription factors 
like NF-κB and AP-1 to the nucleus. In the nucleus, this causes the 
transcription of more inflammatory and pro-inflammatory cytokine 
genes. It also induces the expression of endothelial adhesion proteins 
and chemokines in the synovium which attracts leucocytes to the 
synovium. In addition, activation of the receptor can cause apoptosis in 
cells harbouring intracellular pathogens.
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reported with etanercept, but unless active lupus develops, 
cessation of treatment is not indicated.2,6
Infliximab 
Infliximab is an older generation chimeric human/mouse 
monoclonal antibody and binds soluble and membrane-
associated TNF-α receptors.  Concurrent administration with 
methotrexate or glucocorticosteroids reduces formation of anti-
chimeric antibodies and is recommended.2,6
Golimumab 
This is a humanized monoclonal antibody reducing the risk 
of antibody formation and has a high affinity for soluble and 
membrane bound TNF-α. Adverse effects are associated with the 
inhibition of TNF-α. It is used in moderate to severe rheumatoid 
arthritis in adults.2,6
Adalimumab
Adalimumab is a human IgG1 monoclonal antibody to TNF-α. It 
forms a complex with soluble TNF-α and prevents its interaction 
with TNFα p55 and p75 cell surface receptors. The use of 
adalimumab decreases macrophage and T-cell function.2,6
Non-TNF-α biological immune modulators
Currently, four non-TNF-α biological molecules are available 
to use in the arthritic diseases. Abatacept, rituximab and 
tocilizumab are used in the management of rheumatoid arthritis. 
Ustekinumab is a new monoclonal antibody and is active against 
psoriatic arthritis and psoriasis but not against rheumatoid 
arthritis.5
Abatacept 
Abatacept is a genetically engineered fusion protein consisting 
of the extracellular domain of cytotoxic T-lymphocyte-associated 
antigen (CTLA-4) fused to the hinge region of IgG1. The activation 
of naïve T cells requires the CD80/86 costimulatory molecules on 
dendritic cells to interact with the CD28 molecule on naïve T cells. 
This interaction is required to complete antigen presentation. 
Abatacept blocks T-cell costimulation by preventing the binding 
of CD80/86 to CD28 as shown in Figure 3. This decreases the 
response of naïve T cells to antigen presentation.2,10 
Abatacept is used in both TNF-α naïve patients and in patients 
who have previously failed on TNF-α therapy.6,11 Concurrent 
administration with TNF-α inhibitors is discouraged. Abatacept 
increases the risk for re-activation of latent TB and increases the 
risk for upper respiratory tract infections. Infusion reactions are 
rare.
Rituximab 
Rituximab is a chimeric monoclonal antibody to the CD20 
receptor found on mature B lymphocytes. Its use leads to the 
long-lasting near depletion of B cells in the peripheral blood. 
Rituximab is not used exclusively for the treatment of rheumatoid 
arthritis but also treat cancers like lymphoma. Rituximab is 
indicated in rheumatoid arthritis when patients fail to respond to 
TNF-α inhibitors.12,13 Cell mediated and complement dependent 
cytotoxicity and apoptosis are responsible for the depletion of B 
lymphocytes.
Table 1: TNF-α inhibitors kinetics and indications
TNF-α Inhibitor T½ (Days) Dose and interval Indications
Etanercept (Enbrel) 4.5 25 mg twice weekly  
          or
50 mg once weekly
Subcutaneous
Rheumatoid arthritis,
Psoriasis,
Ankylosing spondylitis,
Juvenile chronic arthritis
Infliximab (Revellex) 9–12 3- 5 mg/kg every 4–8 weeks
Subcutaneous
Rheumatoid arthritis,
Psoriasis,
Ankylosing spondylitis 
Golimumab (Simponi) 14 50 mg/month
Subcutaneous
Rheumatoid arthritis,
Psoriatic arthritis,
Ankylosing spondylitis
Adalimumab (Humira) 10–12 80 mg loading dose,
thereafter 40 mg every 14–20 days
Subcutaneous
Rheumatoid arthritis,
Ankylosing spondylitis, 
Psoriatic arthritis,
Juvenile idiopathic arthritis, 
Plaque psoriasis, 
Crohn’s disease
Figure 3. A schematic diagram showing the binding of abatacept to 
CD80/86 and preventing its interaction with CD28 on naïve T-cells. APC: 
antigen presenting cell; MHC: major histocompatibility complex, TCR: 
T-cell receptor, Ag: antigen, CD28: receptor molecule for CD80/86
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The high dose of rituximab causes an infusion reaction which 
can be managed by pre-treatment with a glucocorticosteroid. 
A skin rash is common with the first treatment but decreases 
with subsequent treatments. In the case of an urticarial rash 
or an anaphylactic reaction, the use of rituximab should be 
discontinued. Rituximab is not associated with the reactivation 
of TB infections, lymphomas or other tumours. However, 
the reactivation of hepatitis B is a concern and concomitant 
antiviral therapy is recommended. Although rare, multifocal 
leukoencephalopathy is a serious adverse reaction associated 
with rituximab.14
Tocilizumab 
Tocilizumab is a humanized monoclonal antibody that binds 
to soluble and membrane bound IL-6 receptors, preventing 
IL-6 mediated signalling. Interleukin 6 is produced by various 
immune cells, including macrophages and fibroblasts, and is 
recognized as an important pro-inflammatory cytokine. IL-6 
regulates T-cell function, the acute phase reaction and terminal 
B-cell differentiation. Binding of IL-6 causes the recruitment of 
two molecules of glycoprotein 130 (gp130) to the receptor.15 The 
IL-6 receptor is expressed on hepatocytes and a subpopulation 
of leucocytes and megakaryocytes. 15
IL-6 combined with transforming growth factor β induces the 
differentiation of naïve T cells to inflammatory Th17 cells. This 
promotes the maturation of B cells toward the production of 
IgG.  In hepatocytes it stimulates the production of acute phase 
reactants like C-reactive protein, serum amyloid A, haptoglobin, 
fibrinogen and α-anti-chymotrypsin. In addition, it decreases the 
hepatic production of transferrin and hepcidin, contributing to 
anaemia of chronic inflammation.15
Used therapeutically, tocilizumab decreases rheumatoid factor, 
acute phase reactants and inflammatory Th17 cells, and reduces 
bone resorption. However, tocilizumab is associated with several 
adverse drug reactions shown in Table 2 and is not recommended 
for patients with hepatic disease.
Ustekinumab
This monoclonal antibody inhibits the function of IL12/IL23 
and is registered in South Africa for the treatment of psoriasis. 
It is effective in treating psoriatic arthritis, psoriasis and Crohn’s 
disease, but has no clinical benefit in rheumatoid arthritis.16 
Ustekinumab binds to the p40 subunit of both IL-12 and IL-23 
and prevents them binding to their respective receptors. IL-12 
is produced by macrophages and promotes the Th1 response, 
activates natural killer cells and together with IL-18 causes 
interferon-γ release.16 The failure of ustekinumab in rheumatoid 
arthritis indicates that these processes are not important in the 
pathogenesis of rheumatoid arthritis. 
Summary of key concepts in the use therapeutic use 
of biological DMARDs
• Biological DMARDs are indicated when therapy with small 
molecule DMARDs fails. 
• Biological agents can be used with or without methotrexate, 
but methotrexate prolongs the therapeutic lifespan of the 
biological agents.
• TNF-α inhibitors are used before the non-TNF-α inhibitors.
• Tuberculosis infections are common with the TNF-α inhibitors 
and latent infections can be reactivated.
• It is advisable to vaccinate patients against common infections.
• Opportunistic fungal viral and bacterial infections are 
common. 
• Biological agents do not effect a cure but contribute to 
achieving a state of remission.
• Withdrawal of biological agents or DMARDs in patients who 
are in remission causes reactivation of the disease.
Table 2. Summary of the non-TNF-α biological DMARDs, their dosage, primary indications and common and serious adverse effects
Immune modulator Dose and interval Indications Adverse effects
Abatacept
(Orencia)
Induction dose: week 0, 2 and 4  500 mg
Thereafter  monthly dose:
< 60 kg: 500 mg
60–100 kg  750 mg
> 100kg : 1000 mg
Intravenous
Rheumatoid arthritis, Juvenile 
idiopathic arthritis
Infusion reactions,
Infections
Rituximab
(Mabthera)
Two IV infusions of 1000 mg two week 
interval 
Repeat 6–9 months
Intravenous
Rheumatoid arthritis, 
Haematological malignancies,
ANCA associated vasculitis,
Non-Hodgkin’s lymphoma,
Chronic lymphocytic lymphoma
Infusion reaction,
Infections,
Reactivation of hepatitis B,
Multifocal leuko-encephalopathy
Tocilizumab
(Actemra)
8 mg every two weeks
Intravenous
Rheumatoid arthritis, 
Systemic juvenile idiopathic arthritis,
Juvenile idiopathic arthritis
Infusion reaction,
Infections,
Dyslipidaemia,
GI perforation
Ustekinumab
(Stelara)
45 mg/100 kg /month (twice) then 45 mg/ 
100 kg every 12 weeks
Intravenous
Psoriatic arthritis,
Plaque psoriasis, 
Crohn’s disease
Infections,
Headache,
Pain – pharynx, larynx,
Myalgia,
Exfoliative dermatitis,
Hypersensitivity,
Malignancies
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Conclusion
The target-specific biological agents are clinically useful 
additions to the DMARDs and improve the chance to achieve 
remission in patients with rheumatoid arthritis. Their crippling 
cost, however, limit their use in resource-poor countries. The risk 
for serious infections in patients on biological DMARDs is of great 
importance and patients require regular monitoring.
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